ethyl 3-amino-3-ethoxyacrylate hydrochloride | 34570-16-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: ethyl 3-amino-3-ethoxyacrylate hydrochloride
• 英文别名: diethyl monoimidicmalonate hydrochloride；ethyl β-amino-β-ethoxyacrylate hydrochloride；ethyl (Z)-3-amino-3-ethoxyprop-2-enoate;hydrochloride
• CAS: 34570-16-6
• 化学式: C₇H₁₃NO₃*ClH
• 分子量: 195.646
• InChiKey: JYGHNNMPKVPTKF-YSMBQZINSA-N

物化性质

• 熔点：
  103-105 °C(lit.)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.33
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  63.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2922509090
• WGK Germany：
  3
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 3-amino-3-ethoxyacrylate, HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 3-amino-3-ethoxyacrylate, HCl
CAS number: 34570-16-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H13NO3.ClH
Molecular weight: 195.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：用于有机合成，还可作为感光材料的中间体。

反应信息

• 作为反应物：
  描述：

  ethyl 3-amino-3-ethoxyacrylate hydrochloride 在 三乙胺 作用下， 以 氯仿 、 水 为溶剂， 反应 1.5h， 生成 ethyl 5-cyanomethyl-1,3,4-oxadiazole-2-acetate
  参考文献：
  名称：

  Elnagdi, Mohamed Hilmy; Ibrahim, Nadia Sobhy; Abdelrazek, Fathy Mohamed, Liebigs Annalen der Chemie, 1988, p. 909 - 912

  摘要：

  DOI：
• 作为产物：
  描述：

  甲基叔丁基醚 、 氰乙酸乙酯 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 ethyl 3-amino-3-ethoxyacrylate hydrochloride
  参考文献：
  名称：

  Pyrimidinecarbamate derivatives as intermediates

  摘要：

  公式为##STR1##的2,4-二取代的6-[3,6-二氢-1(2H)-吡啶基]嘧啶-3-氧化物，其中R.sup.1是较低的烷基或较低的烷氧基-较低的烷基，R.sup.2是氢或--COOR.sup.3，其中R.sup.3是较低的烷基或较低的烷氧基-较低的烷基，这对于制备具有治疗价值的1,2,5,6-四氢吡啶基取代的2-氧代-2H-[1,2,4]噁二唑嘧啶基氨酯很重要。上述公式I的氧化物可以通过将相应的芳基磺酰氧基或烷基磺酰基取代衍生物与1,2,5,6-四氢吡啶反应制备。

  公开号：

  US04549019A1
• 作为试剂：
  描述：

  ethyl 3-amino-3-ethoxyacrylate hydrochloride 、 3-[(4-fluoro-2-nitrophenyl)amino]propanenitrile 在 ethyl 3-amino-3-ethoxyacrylate hydrochloride 作用下， 以75的产率得到1-(2-cyanoethyl)-2-carbethoxymethyl-5-fluorobenzimidazole
  参考文献：
  名称：

  Org. Process Res. Dev. 1999, 3, 260-265

  摘要：

  DOI：

文献信息

• Inhibitors of c-Jun N-terminal kinases
  申请人：Liu Gang

  公开号：US20060173050A1

  公开（公告）日：2006-08-03

  The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.

  本发明涉及作为c-jun N-末端激酶1、2或3（JNK1、JNK2或JNK3）抑制剂的化合物，包含这些化合物的组合物以及这些化合物在预防或治疗由JNK1、JNK2和JNK3激活调控的疾病中的用途。
• Piperazine derivatives as therapeutic agents
  申请人：Knoll Aktiengesellschaft

  公开号：US06114334A1

  公开（公告）日：2000-09-05

  Substituted piperazine compounds of formula I ##STR1## in which HET is a substituted pyrazole, imidazole or 1,2,4-triazole have utility in the treatment of central nervous system disorders, for example depression, anxiety, psychoses (for example schizophrenia), tardive dyskinesia, Parkinson's disease, obesity, hypertension, Tourette's syndrome, sexual dysfunction, drug addiction, drug abuse, cognitive disorders, Alzheimer's disease, senile dementia, obsessive-compulsive behaviour, panic attacks, social phobias, eating disorders and anorexia, cardiovascular and cerebrovascular disorders, non-insulin dependent diabetes mellitus, hyperglycaemia, constipation, arrhythmia, disorders of the neuroendocrine system, stress, prostatic hypertrophy, and spasticity.

  公式I的替代哌嗪化合物##STR1##，其中HET是替代的吡唑啉、咪唑或1,2,4-三唑，在治疗中枢神经系统疾病方面具有实用性，例如抑郁症、焦虑症、精神病（例如精神分裂症）、迟发性运动障碍、帕金森病、肥胖症、高血压、图雷特综合征、性功能障碍、药物成瘾、药物滥用、认知障碍、阿尔茨海默病、老年性痴呆、强迫行为、恐慌发作、社交恐惧症、进食障碍和厌食症、心血管和脑血管疾病、非胰岛素依赖型糖尿病、高血糖症、便秘、心律失常、神经内分泌系统疾病、压力、前列腺肥大和痉挛症。
• A New Route to the Synthesis of 2-Amino-6-(methoxycarbonyl)amino-4-(tetrahydropyridyl)pyrimidine 1-Oxide
  作者：Jean-Claude Muller、Henri Ramuz、Hans-Peter Wagner

  DOI：10.1002/hlca.19830660313

  日期：1983.5.5

  2-amino-6-(methoxycarbonyl)amino-4-(1,2,3,6-tetrahydro-1-pyridyl)pyrimidine 1-oxide (3) is described. Methyl [1-ethoxy-2-(ethoxycarbonyl)-ethylidene]carbamate (5) reacted with guanidine to the pyrimidinecarbamate 6, which was successively transformed into methyl 2-amino-6-(p-tolyslulfonyl)oxy-4-pyrimidinecarbamate (8). Oxidation of 8 led to the corresponding pyrimidine N-oxide 9, a useful starting material to 3.

  描述了一种新的方法来制备2-氨基-6-（甲氧基羰基）氨基-4-（1,2,3,6-四氢-1-吡啶基）嘧啶1-氧化物（3）。[1-乙氧基-2-（乙氧基羰基）-亚乙基]氨基甲酸酯甲基（5）与胍反应生成嘧啶氨基甲酸酯6，然后依次转化为2-氨基-6-（对甲苯磺酰基）氧基-4-嘧啶氨基甲酸酯（8））。氧化8生成相应的嘧啶N-氧化物9，该原料是合成3的有用原料。
• Synthesis and preliminary evaluation of new 1- and 3-[1-(2-hydroxy-3-phenoxypropyl)]xanthines from 2-amino-2-oxazolines as potential A1 and A2A adenosine receptor antagonists
  作者：Stéphane Massip、Jean Guillon、Daniela Bertarelli、Jean-Jacques Bosc、Jean-Michel Léger、Svenja Lacher、Cécile Bontemps、Thibaut Dupont、Christa E. Müller、Christian Jarry

  DOI：10.1016/j.bmc.2005.11.050

  日期：2006.4

  The development of potent and selective adenosine receptor ligands as potential drugs is an active area of research. Xanthines are one of the most important classes of adenosine receptor antagonists and have been widely developed in terms of affinity and selectivity for adenosine receptors. We recently developed new original pathways for the synthesis of xanthine analogues starting from 5-substituted

  有效和选择性腺苷受体配体作为潜在药物的开发是一个活跃的研究领域。黄嘌呤是最重要的一类腺苷受体拮抗剂，在腺苷受体的亲和力和选择性方面已得到广泛发展。我们最近开发了新的原始途径，用于合成黄嘌呤类似物，其起始位置为5取代的2-氨基2-恶唑啉5作为合成子。这些程序使我们能够在黄嘌呤部分的1和3位选择性引入大的，功能化的和β-肾上腺素的2-羟基-3-苯氧基丙基药效基团，从而可以进行进一步的结构修饰。在这项研究中，我们提供了一种从5合成外消旋黄嘌呤衍生物1-4的新途径，并将其评估为腺苷A1，放射性配体结合研究中的A2A和A3受体配体。在黄嘌呤核苷的3-位中2-羟基-3-苯氧丙基部分被很好地耐受，而在黄嘌呤核苷的1-位中引入它导致腺苷受体亲和力大大降低。1,7-二甲基-3- [1-（2-氯-3-苯氧基丙基）]-8-（3,4,5-三甲氧基苯乙烯基）黄嘌呤（2n）是本系列中最有效和选择性最高的A2A拮抗剂（
• [EN] HETEROCYCLIC QUINOLIZINE DERIVED M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 DÉRIVÉ DE LA QUINOLIZINE HÉTÉROCYCLIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011137049A1

  公开（公告）日：2011-11-03

  The present invention is directed to novel 3-oxo-2,3-dihydropyrazolo[4,3-c]quinolizine derived compounds of generic formula (I) or a pharmaceutically acceptable salt thereof, which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及一种新型的3-氧代-2,3-二氢吡唑并[4,3-c]喹啉衍生物，其通用式为(I)或其药学上可接受的盐，它们是M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物治疗由M1受体介导的疾病的用途。